Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1.

The antiviral activities of various dideoxynucleosides against LAV strains of human immunodeficiency viruses type 1 (HIV-1) and type 2 (HIV-2) were evaluated. Significantly more 3'-azido-3'-deoxythymidine was required to inhibit the replication of HIV-2 than HIV-1 in three human cell lines. HIV-2 also appeared more resistant than HIV-1 to other dideoxynucleosides. These results suggest that dideoxynucleosides may be less effective in vivo for HIV-2 infection and that a broader range of clinical isolates of human retroviruses should be examined for drug susceptibility in vitro.
AuthorsD D Richman
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 31 Issue 12 Pg. 1879-81 (Dec 1987) ISSN: 0066-4804 [Print] UNITED STATES
PMID3501941 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antiviral Agents
  • Zidovudine
  • Thymidine
  • Antiviral Agents (pharmacology)
  • Cell Line
  • Drug Resistance, Microbial
  • HIV (drug effects, physiology)
  • Humans
  • T-Lymphocytes (drug effects)
  • Thymidine (analogs & derivatives, pharmacology)
  • Virus Replication (drug effects)
  • Zidovudine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: